

### DAFTAR PUSTAKA

- Abusalah, M.A.H., Gan, S.H., Al-Hatamleh, M.A., Irekeola, A.A., Shueb, R.H. and Yean Yean, C., 2020. Recent advances in diagnostic approaches for Epstein-Barr virus. *Pathogens*, 9(3),p.226. <https://doi.org/10.3390/pathogens9030226>
- Benkoël, L., Biagini, P., Doderò, F., De Lamballerie, X., De Micco, P., Chamlian, A., Lombardo, D., 2009. Immunohistochemical detection of C-100 hepatitis C virus antigen in formaldehyde-fixed paraffin-embedded liver tissue. Correlation with serum, tissue and in situ RT-PCR results. *Eur J Histochem*48, 185. <https://doi.org/10.4081/886>
- Bharat, A., Narayanan, K., Golocheikine, A., Steward, N., Crippin, J., Lisker-Melman, M., Shenoy, S., Lowell, J., Chapman, W.C., Mohanakumar, T., 2007. Elevated Soluble CD30 Characterizes Patients With Hepatitis C Virus-Induced Liver Allograft Cirrhosis. *Transplantation* 84, 1704–1707. <https://doi.org/10.1097/01.tp.0000295973.31877.7b>
- Cai, Q., Cai, J., Fang, Y. and Young, K.H., 2019. Epstein-Barr virus-positive natural killer/T-cell lymphoma. *Frontiers in Oncology*, 9, p.386. <https://doi.org/10.3389/fonc.2019.00386>
- Campuzano-Zuluaga, G., Cioffi-Lavina, M., Lossos, I.S., Chapman-Fredricks, J.R., 2012. CD30 Expression in Diffuse Large B-Cell Lymphoma and Its Relation to Important Clinical and Biological Disease Features. *Blood* 120, 1592–1592. <https://doi.org/10.1182/blood.V120.21.1592.1592>
- Canioni, D., Michot, J.-M., Rabiega, P., Molina, T.J., Charlotte, F., Lazure, T., Davi, F., Settegrana, C., Berger, F., Alric, L., Cacoub, P., Terrier, B., Suarez, F., Sibon, D., Dupuis, J., Feray, C., Tilly, H., Pol, S., Deau Fischer, B., Roulland, S., Thieblemont, C., Leblond, V., Carrat, F., Hermine, O., Besson, C., national ANRS HC13100. <https://doi.org/10.1093/annonc/mdx635>
- Cao, M., Wang, Q., Lingel, A., Zhang, L., 2014. Nuclear factor  $\kappa$ B represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells. *World Journal of Virology* 3, 22–29. <https://doi.org/10.5501/wjv.v3.i4.22>
- Couronné, L., Bachy, E., Roulland, S., Nadel, B., Davi, F., Armand, M., Canioni, D., Michot, J.M., Visco, C., Arcaini, L., Besson, C., Hermine, O., 2018a. From hepatitis C virus infection to B-cell lymphoma. *Ann. Oncol.* 29, 92–
- Dal Maso, L., Franceschi, S., 2006. Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies. *Cancer Epidemiology Biomarkers & Prevention* 15, 2078–2085. <https://doi.org/10.1158/1055-9965.EPI-06-0308>
- Donzel, M., Bonjour, M., Combes, J. D., Broussais, F., Sesques, P., Traverse-Glehen, A., & Martel, C. (2022). Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. *Eclinicalmedicine*, 54, 101674. <https://doi.org/10.1016/j.eclinm.2022.101674>
- Feng, Y., Rao, H., Lei, Y., Huang, Y., Wang, F., Zhang, Y., ... & Shao, J. (2017). CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. *Chinese Journal of Cancer*, 36, <https://doi.org/10.1186/s40880-017-0212-9>
- Foschi, F.G., Gramenzi, A., Castelli, E., Cursaro, C., Pagani, S., Margotti, M., D'Errico, A., Andreone, P., Stefanini, G.F., Bernardi, M., 2000. SOLUBLE CD30 SERUM LEVEL IN

HCV-POSITIVE CHRONIC ACTIVE HEPATITIS: A SURROGATE MARKER OF DISEASE ACTIVITY? *Cytokine* 12, 815–818. <https://doi.org/10.1006/cyto.1999.0653>

- Gong, Q.X., Lu, T.X., Liu, C., Wang, Z., Liang, J.H., Xu, W., Li, J.Y., Zhang, Z.H. and Chen, Q., 2015. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. *International Journal of Clinical and Experimental Pathology*, 8(12), p.15825. PMID: [26884853](https://pubmed.ncbi.nlm.nih.gov/26884853/)
- Gru, A. A., Haverkos, B. H., Freud, A. G., Hastings, J., Nowacki, N. B., Barrionuevo, C., ... & Porcu, P. (2015). The Epstein-Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment. *Current hematologic malignancy reports*, 10, 456-467. <https://doi.org/10.1007%2Fs11899-015-0292-z>
- Hardianti, M.S., Ghazali, R., Sutapa, S.A., Triningsih, F.E., 2016. Histopathology Features of Lymphoma In Yogyakarta, Indonesia. *Asian Pacific Journal of Cancer Prevention*. <https://doi.org/PMID:27797220>
- Horesh, N., Horowitz, N.A., 2014. Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy. *Rambam Maimonides Med J* 5, e0038. <https://doi.org/10.5041/RMMJ.10172>
- Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., Manyam, G.C., Visco, C., Tzankov, A., Liu, W.M., Miranda, R.N., Zhang, L., Montes-Moreno, S. and Dybkær, K., 2013. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. *Blood, The Journal of the American Society of Hematology*, 121(14), pp.2715-2724. <https://doi.org/10.1182/blood-2012-10-461848>
- Hwang, J., Suh, C. H., Won Kim, K., Kim, H. S., Armand, P., Huang, R. Y., & Guenette, J. P. (2021). The incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma: a systematic review and meta-analysis. *Cancers*, 13(8), 1785. <https://doi.org/10.3390/cancers13081785>
- Ikram, S., Ahmad, J., Rehman, I.U. and Durdagi, S., 2020. Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain. *Journal of Molecular Graphics and Modelling*, 101, p.107727. <https://doi.org/10.1016/j.jmgm.2020.107727>
- Iqbal, T., Mahale, P., Turturro, F., Kyvernitakis, A. and Torres, H.A., 2016. Prevalence and association of hepatitis C virus infection with different types of lymphoma. *International journal of cancer*, 138(4), pp.1035-1037. <https://doi.org/10.1002/ijc.29845>
- Jung, J. M., Yang, H. J., Won, C. H., Chang, S. E., Lee, M. W., & Lee, W. J. (2021). Clinicopathological and prognostic study of primary cutaneous extranodal natural killer/T-cell lymphoma, nasal type: A systematic review. *The Journal of Dermatology*, 48(10), 1499-1510. <https://doi.org/10.1111/1346-8138.15972>
- Karube, K., Kakimoto, Y., Tonozuka, Y., & Ohshima, K. (2021). The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. *Expert Review of Hematology*, 14(8), 777-787. <https://doi.org/10.1080/17474086.2021.1955344>
- Kawamoto, K., Miyoshi, H., Suzuki, T., Sasaki, Y., Yamada, K., Yanagida, E., Muto, R., Kiryu, M., Sone, H., Seto, M. and Ohshima, K., 2018. Frequent expression of CD 30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD 30 antibody-based therapy. *Hematological Oncology*, 36(1), pp.166-173. <https://doi.org/10.1002/hon.2482>



**HUBUNGAN EKSPRESI CD30, NS3, DAN EBER DENGAN GAMBARAN KLINIKOPATOLOGI PADA PASIEN LIMFOMA NON HODGKIN SEL T**

Rizki Amalia Juwita, dr. Nungki Anggorowati, Sp.PA (K), Ph.D.; dr. Mardiah Suci Hardianti, Ph.D, Sp.PD-KHOM

UNIVERSITAS  
GADJAH MADA

Universitas Gadjah Mada, 2023 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- Khaled, H., Abu-Taleb, F. and Haggag, R., 2017. Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. *Journal of Advanced Research*, 8(2), pp.131-137. <https://doi.org/10.1016/j.jare.2016.11.005>
- Kim, W. Y., Nam, S. J., Kim, S., Kim, T. M., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2015). Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. *Leukemia & Lymphoma*, 56(6), 1778-1786. <https://doi.org/10.3109/10428194.2014.974048>
- Lee, W. J., Moon, I. J., Shin, H. J., Won, C. H., Chang, S. E., Choi, J. H., & Lee, M. W. (2019). CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes. *International Journal of Dermatology*, 58(6), 688-696. <https://doi.org/10.1111/ijd.14362>
- Libra, M., Gloghini, A., De Re, V., Rupolo, M., Navolanic, P. M., Gasparotto, D., ... & Carbone, A. (2005). Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. *International journal of oncology*, 26(4), 945-950. <https://doi.org/10.3892/ijo.26.4.945>
- Lim M., Ott G., Jaffe E.S., Ferry J.A., Chan J., et al (2022). WHO Classification Of Tumours Of Haematopoietic And Lymphoid Tissues 5<sup>th</sup> edition. IARC: Lyon 2022
- LymphoC study, 2016. In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. PLoS ONE 11, e0156384. <https://doi.org/10.1371/journal.pone.0156384>
- Montes-Mojarro, I.A., Kim, W.Y., Fend, F. and Quintanilla-Martinez, L., 2020, January. Epstein-Barr virus positive T and NK-cell lymphoproliferations: morphological features and differential diagnosis. In *Seminars in Diagnostic Pathology* (Vol. 37, No. 1, pp. 32-46). WB Saunders. <https://doi.org/10.1053/j.semmp.2019.12.004>
- Muta, H., & Podack, E. R. (2013). CD30: from basic research to cancer therapy. *Immunologic research*, 57, 151-158. <https://doi.org/10.1007/s12026-013-8464-1>
- Nijland, M.L., Koens, L., Pals, S.T., Berge, I.J.M. ten, Bemelman, F.J., Kersten, M.J., 2018. Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center caseseries of 25 patients and a review of the literature. *Haematologica* 103, 486–496. <https://doi.org/10.3324/haematol.2017.169987>
- Phan, A., Veldman, R., Lechowicz, M.J., 2016. T-cell Lymphoma Epidemiology: the Known and Unknown. *Curr Hematol Malig Rep* 11, 492–503. <https://doi.org/10.1007/s11899-016-0353-y>
- Qian, X., Guerrero, R.B., Plummer, T.B., Alves, V.F., Lloyd, R.V., 2004. Detection of Hepatitis C Virus RNA in Formalin-Fixed Paraffin-Embedded Sections with Digoxigenin-Labeled cRNA Probes: Diagnostic Molecular Pathology 13, 9–14. <https://doi.org/10.1097/00019606-200403000-00002>
- Qin, C., Huang, Y., Feng, Y., Li, M., Guo, N. and Rao, H., 2018. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases. *Diagnostic pathology*, 13(1), pp.1-8. <https://doi.org/10.1186/s13000-018-0693-0>
- Rattotti, S., Ferretti, V.V., Rusconi, C., Rossi, A., Fogazzi, S., Baldini, L., Pioltelli, P., Balzarotti, M., Farina, L., Ferreri, A.J. and Laszlo, D., 2019. Lymphomas associated with

chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. *Hematological Oncology*, 37(2), pp.160-167. <http://doi.org/10.1002/hon.2575>

- Sabattini, E., Pizzi, M., Tabanelli, V., Baldin, P., Sacchetti, C. S., Agostinelli, C., ... & Pileri, S. A. (2013). CD30 expression in peripheral T-cell lymphomas. *Haematologica*, 98(8), e81-e82. <https://doi.org/10.3324%2Fhaematol.2013.084913>
- Salas, Q., Climent, F., Tapia, G., Riasol, M., Mercadal, S., Domingo Domenech, E., Oliveira, A., Moreno-Velázquez, M., Garcia, O., Aguilera, C., Fernandez de Sevilla, A., Sureda, A., Sancho, J., González Barca, E., 2017. CD30 expression in diffuse large B-cell lymphoma correlates with non- GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. *Hematological Oncology* 35, 290–290. [https://doi.org/10.1002/hon.2439\\_19](https://doi.org/10.1002/hon.2439_19)
- Santoso, M. R., Hardianti, M. S., Indrawati, I., & Anggorowati, N. (2020). CD30 Expression and Its Correlation with Clinicopathologic Features in Indonesian Diffuse Large B-Cell Lymphoma. *Asian Pacific Journal of Cancer Biology*, 5(3), 107-113. <https://doi.org/10.31557/apjcb.2020.5.3.107-113>.
- Sari, IF., Anggorowati, N., Ekspresi Imunohistokimia CD30 dan HCV NS3 Pada Paisein Limfoma Non Hodgkin (LNH) Sel T di Indonesia (2021). Journal online perpustakaan UGM.
- Schulz, T. F. (2009). Cancer and viral infections in immunocompromised individuals. *International journal of cancer*, 125(8), 1755-1763. <https://doi.org/10.1002/ijc.24741>
- Sciallis, A.P., Law, M.E., Inwards, D.J., McClure, R.F., Macon, W.R., Kurtin, P.J., Dogan, A., Feldman, A.L., 2012. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. *Mod Pathol* 25, 983–992. <https://doi.org/10.1038/modpathol.2012.38>
- Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., Patmore, R., Jack, A., Roman, E., 2015. Lymphoma incidence, survival and prevalence 2004- 2014: sub-type analyses from the UK's Haematological Malignancy Research Network. *Br J Cancer* 112, 1575–1584. <https://doi.org/10.1038/bjc.2015.94>
- Suzuki, H., Goto, S., Ikeda, K., Oshima, T., Furukawa, M., & Takasaka, T. (1999). IL-12 receptor beta2 and CD30 expression in paranasal sinus mucosa of patients with chronic sinusitis. *European Respiratory Journal*, 13(5), 1008-1013. <http://doi.org/10.1034/j.1399-3003.1999.13e13.x>
- Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., 2022. WHO Classification Of Tumours Of Haematopoietic And Lymphoid Tissues. IARC: Lyon
- Tse, E., Zhao, W.L., Xiong, J. and Kwong, Y.L., 2022. How we treat NK/T-cell lymphomas. *Journal of Hematology & Oncology*, 15(1), pp.1-13. <https://doi.org/10.1186/s13045-022-01293-5>
- Van der Weyden, C. A., Pileri, S. A., Feldman, A. L., Whisstock, J., & Prince, H. M. (2017). Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. *Blood cancer journal*, 7(9), e603-e603. <https://doi.org/10.1038/bcj.2017.85>



**HUBUNGAN EKSPRESI CD30, NS3, DAN EBER DENGAN GAMBARAN KLINIKOPATOLOGI PADA PASIEN LIMFOMA NON HODGKIN SEL T**

Rizki Amalia Juwita, dr. Nungki Anggorowati, Sp.PA (K), Ph.D.; dr. Mardiah Suci Hardianti, Ph.D, Sp.PD-KHOM

UNIVERSITAS  
GADJAH MADA

Universitas Gadjah Mada, 2023 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- Vannata, B., Arcaini, L., Zucca, E., 2016. Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know? *Therapeutic Advances in Hematology* 7, 94–107. <https://doi.org/10.1177/2040620715623924>
- Wang, W., Nong, L., Liang, L., Zheng, Y., Li, D., Li, X., Li, T., 2020. Extranodal NK/T-cell lymphoma, nasal type without evidence of EBV infection. *Oncol Lett* 20, 2665–2676. <https://doi.org/10.3892/ol.2020.11842>
- Yang, S.-S., Fu, L.-S., Chang, C.-S., Yeh, H.-Z., Chen, G.-H., Kao, J.-H., 2006. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. *J Gastroenterol Hepatol* 21, 1789–1793. <https://doi.org/10.1111/j.1440-1746.2006.04677.x>
- Yi, J. H., Kim, S. J., & Kim, W. S. (2017). Brentuximab vedotin: clinical updates and practical guidance. *Blood research*, 52(4), 243-253. <https://doi.org/10.5045/br.2017.52.4.243>
- Ziarkiewicz, M., Wołosz, D., Dzieciatkowski, T., Wilczek, E., Dwilewicz-Trojaczek, J., Jędrzejczak, W. W., ... & Ziarkiewicz-Wróblewska, B. (2016). Epstein–Barr virus-positive diffuse large B cell lymphoma in the experience of a tertiary medical center in Poland. *Archivum Immunologiae et Therapiae Experimentalis*, 64, 159-169. <https://doi.org/10.1007/s00005-015-0341-2>